论文部分内容阅读
目的:考察甲磺酸酚妥拉明注射液与垂体后叶素注射液在0.9%氯化钠注射液中的配伍稳定性。方法:溶液配伍后,以紫外光谱法测定0、1、2、3、5 h时甲磺酸酚妥拉明含量变化,并测定配伍溶液p H、不溶性微粒数同时做外观检查。结果:甲磺酸酚妥拉明注射液与垂体后叶素注射液在0.9%氯化钠注射液中配伍后,在0~5 h内外观保持无色澄清,p H无明显变化,不溶性微粒与甲磺酸酚妥拉明、垂体后叶素单独配制溶液相比有一定增加,但符合《中国药典》(2010年版)规定;两药配伍后甲磺酸酚妥拉明含量无明显下降。结论:甲磺酸酚妥拉明和垂体后叶素注射液在0.9%氯化钠注射液中同时配伍后的0~5 h内各参数稳定,临床可以在密切观察下配伍后使用,治疗重症肺部大咯血。
Objective: To investigate the compatibility of phentolamine mesylate injection and pituitrin injection in 0.9% sodium chloride injection. Methods: The compatibility of phentolamine mesylate was determined by UV spectrophotometry at 0, 1, 2, 3, and 5 h. The appearance of p H and insoluble particles in the compatibility solution was also examined. Results: After compatibility of phentolamine mesylate injection and pituitrin injection in 0.9% sodium chloride injection, the appearance remained colorless and clear within 0 ~ 5 h, p H had no obvious change, insoluble particles And phentolamine mesylate, vasopressin alone formulated solution has increased, but in line with the “Chinese Pharmacopoeia” (2010 edition) requirements; compatibility of the two drugs did not significantly reduce phentolamine mesylate content. CONCLUSION: The parameters of phentolamine mesylate and pituitrin injection in 0 ~ 5 h after 0.9% sodium chloride injection simultaneously are compatible. The clinical parameters can be observed after compatibility and used to treat severe pulmonary Department of hemoptysis.